INSUBCONTINENT EXCLUSIVE:
Biocon shares surged 3% to an intraday high of Rs 401.55 on the BSE on Wednesday, after its subsidiary, Biocon Biologics, secured the U.S
Food and Drug Administration (FDA) approval for Kirsty (Insulin Aspart-xjhz), 100 units/mL.This marks a significant milestone as Kirsty is
the first and only interchangeable biosimilar to NovoLog (Insulin Aspart) in the United States.Kirsty, a rapid-acting human insulin
analogue, is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus
It will be available in a single-patient-use prefilled pen for subcutaneous use and a multiple-dose vial for subcutaneous and intravenous
(Insulin Glargine-vfgn Injection), the first approved interchangeable biosimilar, available in Europe and Canada since 2022.The news comes
faces a substantial diabetes burden, with 38.4 million people diagnosed, representing approximately 11.6% of the total population
A significant portion, nearly a quarter, remain undiagnosed, and an additional 97.6 million Americans are identified as prediabetic.
Live
market for Insulin Aspart alone saw approximately $1.9 billion in sales in 2024.Biocon Biologics is already a global leader in biosimilars
and insulin production, ranking among the top three global players for rh-Insulin and Insulin Glargine
The company has provided over 9.2 billion doses of insulin globally, with a broad portfolio of basal, mixed, and rapid-acting
insulins.Globally, Biocon Biologics serves over 5.8 million patients annually and boasts a comprehensive portfolio of in-market and
in-development biosimilar products across multiple therapies.Also read: Dolly Khanna bets on this smallcap stock with 1.5% stake purchase in
June quarterThis includes eight products in the United States and seven in Canada, with a robust portfolio of 20 biosimilar assets spanning
multiple therapy areas, including insulins and monoclonal antibodies.On Tuesday, Biocon shares closed 3% higher at Rs 390.20 on the
BSE.(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own
These do not represent the views of TheIndianSubcontinent)
